Previous 10 | Next 10 |
Karuna Therapeutics (NASDAQ: KRTX) , a clinical-stage biotech , is having a record-breaking day. As of 2:25 p.m. ET, the company's shares were up by an eye-popping 70%, surging to an all-time high during Monday's trading session. Although the biotech released its 2022 second...
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Karuna Therapeutics (NASDAQ: KRTX ) stock is rocketing higher on Monday thanks to results from its Phase 3 EMERGENT-2 trial . This trial covers the efficacy, safety, an...
Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
The shares of Karuna Therapeutics ( NASDAQ: KRTX ) surged ~52% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental schizophrenia therapy KarXT met the primary endpoint. The ADRs of Chinese biotech Zai Lab Limited ...
The shares of Karuna Therapeutics ( NASDAQ: KRTX ) surged ~38% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental schizophrenia therapy KarXT met the primary endpoint. The Phase 3 trial named EMERGENT-2 invol...
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative...
Karuna Therapeutics press release ( NASDAQ: KRTX ): Q2 GAAP EPS of -$2.17 misses by $0.10 . Revenue of $5.28M. The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as o...
Met primary and key secondary endpoints in Phase 3 EMERGENT-2 trial of KarXT in schizophrenia The Company plans to submit a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) in mid-2023 Topline data from the Phase 3 EMERGENT-3 trial and ...
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and nega...
News, Short Squeeze, Breakout and More Instantly...
Karuna Therapeutics Inc. Company Name:
KRTX Stock Symbol:
NYSE Market:
Karuna Therapeutics Inc. Website:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 51.9% to $0.1549 on volume of 312,863,578 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $3.51 on volume of 229,852,079 shares SoundHound AI Inc. (SOUN) fell 3.2% to $8.37 on volu...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...